The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly ...

CASTRES, France, Feb. 6, 2023 /PRNewswire/ -- International Rare Disease Day® will be held on February 28, an opportunity for the Pierre Fabre Group to reiterate its commitment in this area, in ...

CASTRES, France, May 22, 2023 /PRNewswire/ -- Following the exclusive licensing agreement with Urovant Sciences GmbH, Pierre Fabre announced today the start of the EU marketing authorization ...